Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas

British Journal of Haematology

Volumn 127, Issue 1, 2004, Pages 40-49

  Drénou, Bernard ^a   Tilanus, Marcel ^b   Semana, Gilbert ^a   Alizadeh, Mehdi ^a   Birebent, Brigitte ^a   Grosset, Jean Marc ^a   Dias, Patricia ^a   Van Wichen, Dick ^b   Arts, Yvonne ^b   De Santis, Dianne ^b   Fauchet, Renée ^a   Amiot, Laurence ^a,c  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Lab d'Hematologie Immunologie   (France)

Author keywords

Flow cytometry; Human leucocyte antigen; Immune escape; Loss of heterozygosity; Lymphoma

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY;

ALLELISM; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC SELECTION; HETEROZYGOSITY LOSS; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MICROSATELLITE MARKER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; TRANSACTIVATION; TRANSCRIPTION REGULATION;

FLOW CYTOMETRY; GENE EXPRESSION; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHOMA, NON-HODGKIN; MICROSATELLITE REPEATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR ESCAPE;

EID: 4944223346     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05151.x     Document Type: Article

References (34)

1. Amiot, L., Onno, M., Lamy, T., Dauriac, C., Le Prise, P.Y., Fauchet, R. & Drenou, B. (1998) Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. British Journal of Haematology, 100, 655-663.
2. Bea, S., Lopez-Guillermo, A., Ribas, M., Puig, X., Pinyol, M., Carrio, A., Zamora, L., Soler, F., Bosch, F., Stilgenbauer, S., Colomer, D., Miro, R., Montserrat, E. & Campo, E. (2002) Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). American Journal of Pathology, 161, 957-968.
3. Berglund, M., Enblad, G., Flordal, E., Lui, W.O., Backlin, C., Thunberg, U., Sundstrom, C., Roos, G., Allander, S.V., Erlanson, M., Rosenquist, R., Larsson, C. & Lagercrantz, S. (2002) Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. Modern Pathology, 15, 807-816.
4. Brady, C.S., Bartholomew, J.S., Burt, D.J., Duggan-Keen, M.F., Glenville, S., Telford, N., Little, A.M., Davidson, J.A., Jimenez, P., Ruiz-Cabello, F., Garrido, F. & Stern, P.L. (2000) Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens, 55, 401-411.
5. Drenou, B., Le Friec, G., Bernard, M., Pangault, C., Grosset, J.M., Lamy, T., Fauchet, R. & Amiot, L. (2002) Major histocompatibility complex abnormalities in non-Hodgkin lymphomas. British Journal of Haematology, 119, 417-424.
6. Feenstra, M., Verdaasdonk, M., van der Zwan, A.W., de Weger, R., Slootweg, P. & Tilanus, M. (2000) Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Laboratory Investigation, 80, 405-414.
7. Ferrone, S. & Marincola, P.M. (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunology Today, 16, 487-494.
8. Feuillard, J., Jacob, M.C., Valensi, F., Maynadie, M., Gressin, R., Chaperot, L., Arnoulet, C., Brignole-Baudouin, F., Drenou, B., Duchayne, E., Falkenrodt, A., Garand, R., Homolle, E., Husson, B., Kuhlein, E., Le Calvez, G., Sainty, D., Sotto, M.F., Trimoreau, F. & Bene, M.C. (2002) Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood, 99, 1556-1563.
9. Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F. & Stern, P.L. (1993) Natural history of HLA expression during tumour development. Immunology Today, 14, 491-499.
10. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J.J., Lopez-Botet, M., Duggan-Keen, M. & Stern, P.L. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunology Today, 18, 89-95.
11. Gobin, S.J., Peijnenburg, A., van Eggermond, M., van Zutphen, M., van den Berg, R. & van den Eisen, P.J. (1998) The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes. Immunity, 9, 531-541.
12. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B. & Gatter, K.C. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
13. Hernandez, J.M., Garcia, J.L., Gutierrez, N.C., Mollejo, M., Martinez-Climent, J.A., Flores, T., Gonzalez, M.B., Piris, M.A. & San Miguel, J.F. (2001) Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. American Journal of Pathology, 158, 1843-1850.
14. Jimenez, P., Canton, J., Collado, A., Cabrera, T., Serrano, A., Real, L.M., Garcia, A., Ruiz-Cabello, F. & Garrido, F. (1999) Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. International Journal of Cancer, 83, 91-97.
15. Jordanova, E.S., Philippe, K., Giphart, M.J., Schuuring, E. & Kluin, P.M. (2003) Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics, 17, 17.
16. Juszczynski, P., Kalinka, E., Bienvenu, J., Woszczek, G., Borowiec, M., Robak, T., Kowalski, M., Lech-Maranda, E., Baseggio, L., Coiffier, B., Salles, G. & Warzocha, K. (2002) Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood, 100, 3037-3040.
17. Kennedy, L.J., Poulton, K.V., Thomson, W., Williams, F., Midlleton, D., Howell, W.M., Tarassi, K., Papasteriades, C., Albert, E., Fleischhaueur, K., Chandanayingyong, D., Tiercy, J.M., Juji, T., Tokunaga, K. & Oilier, W.E.R. (1997) HLA Class I DNA typing using sequence specific oligonucleotide probes (SSOP). In: Genetic Diversity of HLA functional and Medical Implication, Vol. 1. (ed. by D. Charron), pp. 216-225. EDK, Paris.
18. th International Histocompatibility Workshop and Congress, Vol. I & Vol. II, (ed. by H. Ja & D.B.). IHWG Press, Seattle, USA.
19. Koopman, L.A., Corver, W.E., van der Slik, A.R., Giphart, M.J. & Fleuren, G.J. (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. Journal of Experimental Medicine, 191, 961-976.
20. Landmann, S., Muhlethaler-Mottet, A., Bernasconi, L., Suter, T., Waldburger, J.M., Masternak, K., Arrighi, J.F., Hauser, C., Fontana, A. & Reith, W. (2001) Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. Journal of Experimental Medicine, 194, 379-391.
21. Libura, J., Bettens, F., Radkowski, A., Tiercy, J.M. & Piguet, P.P. (2002) Polymorphic tumor necrosis factors microsatellite TNFa4 is associated with resistance of Hodgkin lymphoma to chemotherapy and with replapses after therapy. Anticancer Research, 22, 921-926.
22. Martinez-Climent, J.A., Alizadeh, A.A., Segraves, R., Blesa, D., Rubio-Moscardo, F., Albertson, D.G., Garcia-Conde, J., Dyer, M.J., Levy, R., Pinkel, D. & Lossos, I.S. (2002) Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood, 24, 24.
23. Ortmann, B., Copeman, J., Lehner, P.J., Sadasivan, B., Herberg, J.A., Grandea, A.G., Riddell, S.R., Tampe, R., Spies, T., Trowsdale, J. & Cresswell, P. (1997) A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science, 277, 1306-1309.
24. Parham, P., Barnstable, C.J. & Bodmer, W.F. (1979) Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. Journal of Immunology, 123, 342-349.
25. Randerson, J., Cawkwell, L., Jack, A., Lewis, F., Johnson, P., Evans, P., Barrans, S. & Morgan, G.J. (1996) Fluorescent polymerase chain reaction of a panel of CA repeats on chromosome 6 in the indolent phase of follicular centre cell lymphoma. British Journal of Cancer, 74, 942-946.
26. Riemersma, S.A., Jordanova, E.S., Schop, R.F., Philippe, K., Looijenga, L.H., Schuuring, E. & Kluin, P.M. (2000) Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood, 96, 3569-3577.
27. Rigaud, G., Moore, P.S., Taruscio, D., Scardoni, M., Montresor, M., Menestrina, F. & Scarpa, A. (2001) Alteration of chromosome arm 6p is characteristic of primary mediastinal B-cell lymphoma, as identified by genome-wide allelotyping. Genes, Chromosomes and Cancer, 31, 191-195.
28. Rosa, F., Berissi, H., Weissenbach, J., Maroteaux, L., Fellous, M. & Revel, M. (1983) The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO Journal, 2, 239-243.
29. Schop, R.F., Kuehl, W.M., Van Wier, S.A., Ahmann, G.J., Price-Troska, T., Bailey, R.J., Jalal, S.M., Qi, Y., Kyle, R.A., Greipp, P.R. & Fonseca, R. (2002) Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood, 100, 2996-3001.
30. Stephens, R., Horton, R., Humphray, S., Rowen, L., Trowsdale, J. & Beck, S. (1999) Gene organisation, sequence variation and isochore structure at the centromeric boundary of the human MHC. Journal of Molecular Biology, 291, 789-799.
31. Stokke, T., DeAngelis, P., Smedshammer, L., Galteland, E., Steen, H.B., Smeland, E.B., Delabie, J. & Holte, H. (2001) Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. British Journal of Cancer, 85, 1900-1913.
32. Ting, J.P. & Trowsdale, J. (2002) Genetic control of MHC class II expression. Cell, 109(Suppl.), S21-S33.
33. Tongio M.M., Doxiadis, I., Laforet, M., Schreuder, G.M.Th., Froelich, N., Semana, G., Pratico, L. & Fauchet, R. (1997) 12th International Histocompatibility Workshop HLA class I monoclonal antibodies study. In: Genetic diversity of HLA Functional and Medical Implication, Vol. 1. (ed. by D. Charron), pp. 7-11. EDK, Paris.
34. Warzocha, K., Ribeiro, P., Bienvenu, J., Roy, P., Chariot, C., Rigal, D., Coiffier, B. & Salles, G. (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood, 91, 3574-3581.